Aviragen Therapeutics Aktie
WKN DE: A2AG64 / ISIN: US0537611024
13.09.2024 13:40:41
|
Atea Pharma's Phase 3 SUNRISE-3 Study Of Bemnifosbuvir To Treat Covid-19 Fails
(RTTNews) - Atea Pharmaceuticals, Inc. (AVIR) Friday said its Phase 3 SUNRISE-3 study of bemnifosbuvir for the treatment of Covid-19 failed to meet the primary goal.
In the study, high-risk patients with mild or moderate COVID-19 were randomized to receive bemnifosbuvir or placebo. The trial did not meet the primary endpoint of a statistically significant reduction in all-cause hospitalization or death through day 29.
Bemnifosbuvir is in Phase 2 study in combination with ruzasvir for the treatment of hepatitis c virus (HCV) infection. The company plans to announce additional results from the study in the fourth quarter.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Aviragen Therapeutics Incmehr Nachrichten
Keine Nachrichten verfügbar. |